Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of pSS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: - Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? - Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? - What are the blood levels of RSLV-132 over time? - What is the immune (antibody) response in the body to RSLV-132? - What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06440525
Study type Interventional
Source Resolve Therapeutics
Contact James Posada
Phone (208) 727-7010
Email jp@resolvebio.com
Status Not yet recruiting
Phase Phase 2
Start date September 1, 2024
Completion date July 2026

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03140111 - LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients N/A
Not yet recruiting NCT06049368 - 68Ga-P16-093 PET/CT Imaging in the Salivary Gland Phase 1/Phase 2
Not yet recruiting NCT03614299 - Eye Dryness Evaluation in Primary Sjögren's Syndrome
Not yet recruiting NCT03126383 - Inflammatory Myopathies in Primary Sjögren's Syndrome N/A
Recruiting NCT04830644 - A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. Phase 2
Not yet recruiting NCT03765593 - Biomarkers in Primary Sjögren's Syndrome
Completed NCT01081184 - Neurotrophins Implications in Primary Sjögren Syndrome N/A
Completed NCT05670535 - Sjögren and Gynecologic Considerations
Completed NCT03226444 - Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome Phase 1/Phase 2
Completed NCT04816370 - Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions N/A
Completed NCT05380804 - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Terminated NCT04700280 - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS) Phase 2
Completed NCT03130062 - Resistance Exercise in Woman With Primary Sjörgen Syndrome. N/A
Completed NCT04093531 - Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome Phase 1
Recruiting NCT03509064 - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
Completed NCT04224454 - Vaccine Coverage and Primary Sjögren'Syndrome
Completed NCT04960605 - Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome N/A
Recruiting NCT06361745 - Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases N/A